A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)

NCT04395456 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)

Interventions

DRUG: AMY-101
OTHER: WFI 5% glucose

Sponsor

Amyndas Pharmaceuticals S.A.